Novartis Skin Cancer Drug Combination Involving Spartalizumab Fails Clinical Trial
Swiss pharmaceutical company Novartis AG (NYSE: NVS) announced Saturday that the phase three COMBI-i trial for a combination of drugs against a type of advanced skin cancer didn't meet the clinical requirements of the evaluation.